An in situ modification sorbent for magnetic dispersive micro solid-phase extraction of anti-inflammatory drugs in the human urine sample before their determination with high-performance liquid chromatography

Zomoorodi, Zohreh Bagheri; Masrournia, Mahboubeh; Abedi, Mohammad Reza

doi:10.1007/s11696-021-01761-1

Cited by 8 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…coating materials used in the experimental conditions [23,24]), it would seem that the highest extraction results would be obtained when the DDA cation forms an irregular bilayer. The NR4 + headgroups from the first layer bind to the silica coating of the NP cores via electrostatic interactions, and the long alkyl chains of the first and second layers are bound by Van der Waals forces, while the NR4 + groups of the second layer are directed towards the hydrophilic matrix (plasma/urine samples), causing the positively charged analytes to interact with the alkyl chains of the DDA cation in the irregular bilayer due to hydrophobic and other electrostatic interactions (i.e., Van der Waals forces) [25][26][27].…”

Section: Amount Of Ddabmentioning

confidence: 99%

Magnetic Solid-Phase Microextraction Protocol Based on Didodecyldimethylammonium Bromide-Functionalized Nanoparticles for the Quantification of Epirubicin in Biological Matrices

et al. 2023

View full text Add to dashboard Cite

Due to epirubicin’s (EPI) narrow therapeutic index and risk of cardiotoxicity, it is critical to monitor concentrations of this drug when being used to treat cancer patients. In this study, a simple and fast magnetic solid-phase microextraction (MSPME) protocol for the determination of EPI in plasma and urine samples is developed and tested. Experiments were performed using prepared Fe3O4-based nanoparticles coated with silica and a double-chain surfactant—namely, didodecyldimethylammonium bromide (DDAB)—as a magnetic sorbent. All the prepared samples were analyzed via liquid chromatography coupled with fluorescence detection (LC-FL). The validation parameters indicated good linearity in the range of 0.001–1 µg/mL with a correlation coefficient > 0.9996 for plasma samples, and in the range of 0.001–10 µg/mL with a correlation coefficient > 0.9997 for urine samples. The limit of detection (LOD) and limit of quantification (LOQ) for both matrices were estimated at 0.0005 µg/mL and 0.001 µg/mL, respectively. The analyte recovery after sample pretreatment was 80 ± 5% for the plasma samples and 90 ± 3% for the urine samples. The developed method’s applicability for monitoring EPI concentrations was evaluated by employing it to analyze real plasma and urine samples collected from a pediatric cancer patient. The obtained results confirmed the proposed MSPME-based method’s usefulness, and enabled the determination of the EPI concentration–time profile in the studied patient. The miniaturization of the sampling procedure, along with the significant reduction in pre-treatment steps, make the proposed protocol a promising alternative to routine approaches to monitoring EPI levels in clinical laboratories.

show abstract